Serum ANGPTL2 levels reflect clinical features of breast cancer patients: Implications for the pathogenesis of breast cancer metastasis

International Journal of Biological Markers

Volumn 29, Issue 3, 2014, Pages e239-e245

  Oike, Yuichi ^a,d   Yamamoto, Yutaka ^b   Nakano, Masahiro ^a   Masuda, Tetsuro ^a   Odagiri, Haruki ^a   Horiguchi, Haruki ^a   Miyata, Keishi ^a   Kadomatsu, Tsuyoshi ^a   Motokawa, Ikuyo ^a   Okada, Seiji ^c   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

ANGPTL2; Breast cancer; Metastasis; Nuclear grade; Triple negative

Indexed keywords

ANGIOPOIETIN LIKE PROTEIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PEPTIDES AND PROTEINS; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ANGIOPOIETIN; ANGPTL2 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; PAGET NIPPLE DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTIGRAPHY; AGED; ANIMAL; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; DISEASE COURSE; MCF 7 CELL LINE; METASTASIS; MIDDLE AGED; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE; VERY ELDERLY; XENOGRAFT; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETINS; ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HETEROGRAFTS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM METASTASIS; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84899478430     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000080     Document Type: Article

References (21)

1. Boyle P, Levin B. World Cancer Report 2008. Lyon: IARC press; 2008.
2. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2011; 11(6): 479-497.
3. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005; 5(8): 591-602.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6): 883-899.
5. Aoi J, Endo M, Kadomatsu T, et al. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res. 2011; 71(24): 7502-7512.
6. Endo M, Nakano M, Kadomatsu T, et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res. 2012; 72(7): 1784-1794.
7. Okada T, Tsukano H, Endo M, et al. Synoviocyte-derived angiopoietin-like protein 2 contributes to synovial chronic inflammation in rheumatoid arthritis. Am J Pathol. 2010; 176(5): 2309-2319.
8. Tabata M, Kadomatsu T, Fukuhara S, et al. Angiopoietinlike protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009; 10(3): 178-188.
9. Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J. 2011; 278(4): 559-564.
10. Rigamonti N, De Palma M. A role for angiopoietin-2 in organ-specific metastasis. Cell Rep. 2013; 4(4): 621-623.
11. Minami T, Jiang S, Schadler K, et al. The calcineurin-NFATangiopoietin- 2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep. 2013; 4(4): 709-723.
12. Holopainen T, Saharinen P, D’Amico G, et al. Effects of angiopoietin- 2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst. 2012; 104(6): 461-475.
13. Semenza GL. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene. 2013; 32(35): 4057-4063.
14. Zhang H, Wong CC, Wei H, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012; 31(14): 1757-1770.
15. Odagiri H, Kadomatsu T, Endo M, et al. The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through integrin α5β1, p38 MAPK, and matrix metalloproteinases. Sci Signal. 2014; 7(309): 2004 612.
16. Zheng J, Umikawa M, Cui C, et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature. 2012; 485(7400): 656-660.
17. Khatcheressian JL, Wolff AC, Smith TJ, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006; 24(31): 5091-5097.
18. Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol. 2003; 30(3): 338-348.
19. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002; 38(9): 1189-1193.
20. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat. 1998; 52(1-3): 239-259.
21. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer. 1990; 65(2): 193-199.